Alnylam Pharmaceuticalsvs.Vertex Pharmaceuticals
ALNY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 4.2× larger than Alnylam Pharmaceuticals by market cap; Vertex Pharmaceuticals trades at the lower P/E (29.0 vs 37.2); year to date, Vertex Pharmaceuticals leads (+11.0% vs −43.5%).
Side by side
| ALNY | VRTX | |
|---|---|---|
| Market cap | $30B | $128B |
| Price | $232.68 | $510.08 |
| Today | +3.6% | +1.4% |
| Return YTD | −43.5% | +11.0% |
| Return 1Y | −50.2% | +19.5% |
| Since June 26, 2026 | −20.1% | +3.8% |
| P/E | 37.2 | 29.0 |
| P/S | 6.3 | 10.1 |
| P/B | 22.2 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More ALNY & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.